Humanigen Inc. (HGEN) Prices 5M Share Common Offering at $18.50/Sh

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Humanigen Inc. (HGEN) Prices 5M Share Common Offering at $18.50/Sh

Humanigen Inc. (HGEN) Announces Proposed Public Offering of 5M Shares of Common Stock

March 29, 2021 4:11 PM EDT

Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate lenzilumabTM, today announced that it has commenced an underwritten public offering 5,000,000 shares of its common stock. In connection with this... More

Pre-Open Stock Movers 03/29: (HGEN) (FLY) (HMHC) Higher; (ORPH) (NMR) (CS) Lower (more...)

March 29, 2021 9:29 AM EDT

Today's Pre-Open Stock Movers:

Humanigen, Inc. (Nasdaq: HGEN) 65.3% HIGHER; announced positive topline results from its Phase 3 clinical trial evaluating the efficacy and safety of lenzilumab in patients hospitalized with COVID-19. Trial results showed that patients who received lenzilumab and other treatments, including steroids and/or remdesivir, had a 54% greater relative likelihood of survival without the need for IMV compared with patients receiving placebo and other treatments. These results are statistically significant.

Orphazyme A/S (NASDAQ: ORPH) 32% LOWER; announced... More

Humanigen Inc. (HGEN) Reports Positive Phase 3 Topline Results Demonstrating That Lenzilumab Improves Survival Without Need for Mechanical Ventilation in Hospitalized Patients With COVID-19

March 29, 2021 7:06 AM EDT

Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate, lenzilumab, today announced positive topline results from its Phase 3 clinical trial evaluating the efficacy and safety of lenzilumab in patients hospitalized with COVID-19. Trial results showed that patients who received lenzilumab and other treatments, including steroids and/or remdesivir, had a 54% greater relative likelihood of survival without the need for IMV compared with patients receiving placebo and other treatments. These results are statistically significant.

The results from our Phase 3 clinical... More